Baker Biotech Capital (GP), LLC
CIK 1244389 · last filed 2012-03-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$410.17M
Companies
10
Total Filings
42
Lifetime Open-Market Net
-$24.44M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 1,484,977 | — | — | $8.49M | 7 | 2012-03-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 1,966,090 | — | — | $8.89M | 6 | 2011-12-16 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 912,719 | — | — | -$5.86M | 1 | 2011-08-03 |
| INCY | Director | 3,485,752 | $117.67 | $410.17M | $10.94M | 7 | 2009-03-05 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | 10%+ Owner | 1,646,964 | — | — | $6.18M | 2 | 2008-12-19 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 12,301 | $7.22 | $88.9K | -$1.02M | 4 | 2008-09-30 |
| NEUROGEN CORP (NRGN) Delisted | Director | — | — | — | $0 | 1 | 2008-04-15 |
| Seagen Inc. (SGEN) Delisted | Director | 3,933,090 | $228.74 | $899.66M | -$50.86M | 3 | 2008-03-14 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 2,251,202 | — | — | $2.10M | 1 | 2008-01-09 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 521,466 | — | — | -$3.30M | 3 | 2007-12-04 |
Recent Filings · Page 5 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-02-16 | Seagen Inc. (SGEN) Delisted | Mixed | −1,148,346 | -$26.27M | EDGAR |
| 2007-01-26 | — | Buy (P) | +50,829 | $304.8K |
Showing 41–42 of 42
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.